[1]李 焰,何 山,鄭 軻,等.化療后續用三苯氧胺對乳腺癌患者激素水平的影響[J].醫學信息,2019,(20):133-135.[doi:10.3969/j.issn.1006-1959.2019.20.041]
 LI Yan,HE Shan,ZHENG Ke,et al.Effect of Chemotherapy Followed by Tamoxifen on Hormone Levels in Patients with Breast Cancer[J].Medical Information,2019,(20):133-135.[doi:10.3969/j.issn.1006-1959.2019.20.041]
點擊復制

化療后續用三苯氧胺對乳腺癌患者激素水平的影響()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年20期
頁碼:
133-135
欄目:
藥物與臨床
出版日期:
2019-10-15

文章信息/Info

Title:
Effect of Chemotherapy Followed by Tamoxifen on Hormone Levels in Patients with Breast Cancer
文章編號:
1006-1959(2019)20-0133-03
作者:
李 焰何 山鄭 軻張艷珍李燕茹
(四川省宜賓市第二人民醫院乳腺甲狀腺外科,四川 宜賓 644000)
Author(s):
LI YanHE ShanZHENG KeZHANG Yan-zhenLI Yan-ru
(Department of Breast and Thyroid Surgery,the Second People's Hospital of Yibin City,Yibin 644000,Sichuan,China)
關鍵詞:
乳腺癌三苯氧胺雌二醇黃體生成素卵泡刺激素
Keywords:
reast cancerTamoxifenEstradiolLuteinizing hormoneFollicle stimulating hormone
分類號:
R445.1
DOI:
10.3969/j.issn.1006-1959.2019.20.041
文獻標志碼:
A
摘要:
目的 探討乳腺癌患者化療后續用三苯氧胺對激素水平的影響。方法 選取2015年1月~2018年12月我院收治的乳腺癌患者82例,采用隨機數字表法分為繼用三苯氧胺組(n=40)及停用三苯氧胺組(n=42),比較兩組不同時間點(T0、T1、T2、T3、T4)E2、LH、FSH水平變化情況。結果 兩組E2水平均較治療前升高,差異具有統計學意義(P<0.05);FSH、LH水平較治療前升高,但差異無統計學差異(P>0.05)。繼用三苯氧胺組不同時間點E2、FSH、LH水平比較,差異無統計學意義(P>0.05);停用三苯氧胺組T3、T4時間點E2水平較T1、T2 時間點低,差異有統計學意義(P<0.05),不同時間點FSH、LH水平比較,差異無統計學差異(P>0.05)。結論 化療后續用三苯氧胺可影響乳腺癌患者E2水平,對于FSH及LH水平無明顯影響,服用三苯氧胺期間對卵巢功能的判斷應停藥后多次測量。
Abstract:
Objective To investigate the effect of tamoxifen on hormone levels in patients with breast cancer after chemotherapy.Methods A total of 82 patients with breast cancer admitted to our hospital from January 2015 to December 2018 were enrolled. The randomized digital table method was divided into the tamoxifen group (n=40) and the tamoxifen group (n=42). The changes of E2, LH and FSH levels at different time points (T0,T1,T2,T3,T4) were compared between the two groups.Results The E2 levels in the two groups were higher than those before treatment, the difference was statistically significant (P<0.05). The levels of FSH and LH were higher than those before treatment, but the difference was not statistically significant (P>0.05). There were no significant differences in the levels of E2, FSH and LH between the tamoxifen groups at different time points (P>0.05). The levels of E2 at T3 and T4 in the tamoxifen group were lower than those at T1 and T2, the difference was statistically significant(P<0.05), there was no significant difference in FSH and LH levels at different time points (P>0.05).Conclusion The subsequent use of tamoxifen in chemotherapy can affect the E2 level of breast cancer patients. There is no significant effect on the levels of FSH and LH. The judgment of ovarian function during tamoxifen should be measured after repeated withdrawal.

參考文獻/References:

[1]Yu Z,Guo X,Jiang Y,et al.Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive:a systemic review and network meta-analysis[J].Breast Cancer,2017,25(1):8-16. [2]李焰,蒲玉平,鄭軻,等.化療對乳腺癌患者激素水平及月經狀態的影響[J].現代生物醫學進展,2018,18(12):157-160,174. [3]黃兵江,樊濤,鄭靜,等.絕經前乳腺癌治療手段與閉經相關性的研究進展[J].實用醫學雜志,2018,34(2):331-334. [4]Gradishar WJ,Anderson BO,Balassanian R,et al.Invasive Breast Cancer Version1.2016,NCCN Clinical Practice Guidelines in Oncology[J].Journal of the National Comprehensive Cancer Network,2016,14(3):324. [5]中國抗癌協會乳腺癌專業委員會.中國絕經前女性乳腺癌患者輔助治療后絕經判斷標準及芳香化酶抑制劑臨床應用共識[J].中國癌癥雜志,2012,22(3):321-323. [6]中國抗癌協會乳腺癌專業委員會.中國早期乳腺癌卵巢功能抑制臨床應用專家共識(2018年版)[J].中國癌癥雜志,2018,28(11):76-85. [7]中國抗癌協會乳腺癌專業委員會.中國抗癌協會乳腺癌診治指南與規范(2015版)[J].中國癌癥雜志,2015,25(9):692-753. [8]楊慧芬,羅華,楊歐歐,等.絕經前Luminal型乳腺癌患者血清生殖激素水平與內分泌治療后血管舒縮功能障礙的相關性研究[J].浙江創傷外科,2016(1):1-4. [9]王華龍,王鴻波,單世勝,等.阿那曲唑和他莫昔芬對絕經后乳腺癌患者子宮內膜、血脂代謝、免疫功能和性激素的影響[J].解放軍醫藥雜志,2018,30(5):40-43. [10]楊新明,吳紹洋,陳莉麗,等.三苯氧胺對乳腺癌圍絕經期患者性激素水平的影響[J].中國醫藥導報,2011,8(30):74-75. [11]Madeddu C,Gramignano G,Kotsonis P,et al.Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer:A report of two cases[J].Oncology Letters,2014,8(3):1279-1282. [12]閆莉.方玄駒膠囊聯合他莫昔芬對多囊卵巢綜合征不孕患者性激素水平變化及妊娠率的影響[J].中國民間療法,2019,27(4):71-73. [13]王健,趙冬梅,范宇.乳腺癌患者長期口服三苯氧胺對激素水平影響[J].中國實用醫藥,2013,8(31):239-240.

相似文獻/References:

[1]董 云.SPECT/CT 雙時相99mTc- MIBI斷層顯像 在乳腺癌診斷中的應用[J].醫學信息,2018,(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
 DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,(20):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]于 東.平消片為主組合方案治療乳腺增生癥臨床分析[J].醫學信息,2018,(08):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]
 YU Dong.Clinical Analysis of the Combination of Pingxiao Tablets in the Treatment of Mammary Hyperplasia[J].Medical Information,2018,(20):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]
[3]李建輝,祝旭龍.乳腺癌的治療管理——把好生活質量關[J].醫學信息,2018,(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]楊玉峰,李 強,曲國紅,等.乳腺癌術前巴德槍穿刺檢測ER、PR的臨床研究[J].醫學信息,2018,(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
 YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,(20):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]劉 曼,厲瑪倩倩,徐潤潤,等.延續性護理對乳腺癌術后化療患者生活質量與 健康知識水平的影響[J].醫學信息,2018,(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
 LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,(20):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[6]張艷萍,曹 玉,孫國平.服用阿司匹林對乳腺癌患者生存獲益的Meta分析[J].醫學信息,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
 ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Medical Information,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[7]鐘 磊,謝海燕,林 霖.電化學發光免疫分析技術檢測腫瘤標志物在乳腺癌診斷中的應用[J].醫學信息,2018,(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
 ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[8]胡平華,黃 勤,李志華.含卡培他濱方案一線或后線治療晚期乳腺癌的效果對比[J].醫學信息,2018,(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
 HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,(20):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[9]闕海濤,曹 斌,秦志剛.EGFL7在乳腺癌中的研究進展[J].醫學信息,2018,(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
 QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Medical Information,2018,(20):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[10]張文婧,宋 冰.HER-2陽性乳腺癌分子靶向治療進展[J].醫學信息,2018,(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
 ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Medical Information,2018,(20):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]

更新日期/Last Update: 2019-10-15
重庆时时开奖号码k线图